Pipeline

Autologous Therapies
Product Candidate Targeted Indications Product
Development
Pre-Clinical Phase I Phase II Phase III
TT10
EBVSTs
Nasopharyngeal Cancer
TT12
Armored HPVSTs
Cervical Cancer
TT14
Armored GPC3-CAR VSTs
GPC3+ Cancers
TT16
HER2-CAR VSTs + CAdVEC
HER2+ Cancers
TT18
Multi CAR VZVSTs
Pediatric Gliomas
Allogeneic Therapy
Product Candidate Targeted Indications Product
Development
Pre-Clinical Phase I Phase II Phase III
TT10x
Allogeneic EBVSTs
EBV+ Lymphoproliferative Diseases

TT12, TT16, and TT10x are Investigator-initiated Trials sponsored by Tessa. All of Tessa’s programmes are not yet being offered for sale and are currently undergoing investigation. Accordingly, Tessa makes no claim as to their safety and effectiveness for the purposes for which they are under investigation.

Autologous Therapies
Product / Targeted Indications Product
Dev
Pre-Clinical Phase I Phase II Phase III
TT10
EBVSTs / Nasopharyngeal Cancer
TT12
Armored HPVSTs / Cervical Cancer
TT14
Armored GPC3-CAR VSTs / GPC3+ Cancers
TT16
HER2-CAR VSTs + CAdVEC / HER2+ Cancers
TT18
Multi CAR VZVSTs / Pediatric Gliomas
Allogeneic Therapy
Product / Targeted Indications Product
Dev
Pre-Clinical Phase I Phase II Phase III
TT10x
Allogeneic EBVSTs / EBV+ Lymphoproliferative Diseases

TT12, TT16, and TT10x are Investigator-initiated Trials sponsored by Tessa. All of Tessa’s programmes are not yet being offered for sale and are currently undergoing investigation. Accordingly, Tessa makes no claim as to their safety and effectiveness for the purposes for which they are under investigation.

Indications

Epstein-Barr Virus-Specific T Cells (EBVSTs) for Nasopharyngeal Cancer (NPC)

Using our proprietary Virus-Specific T cell (VST) platform, we are able to target specific Epstein-Barr Virus (EBV) proteins that are present on EBV-positive tumors.

Our EBVSTs extracted from patient’s blood are enhanced for anti-tumor potency, selectively activated and expanded ex vivo before infusion back into the patient

Trial Name:

TT10: NPC EBVST (Phase III)

Indication: Nasopharyngeal cancer (NPC)
US FDA Orphan Drug and Fast Track Designation

Enrollment Status: Recruiting

Trial Number: NCT02578641

A Multicentre, Randomized, Open-Label, Phase III Clinical Trial of Gemcitabine and Carboplatin Followed by Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine and Carboplatin as First Line Treatment for Advanced Nasopharyngeal cancer Patients.

Learn more at Clinicaltrials.gov

Locations

United States

  • California, United States
  • Massachusetts, United States
  • Texas, United States

Malaysia

Singapore

Taiwan

Thailand

Human Papillomavirus-Specific T Cells (HPVSTs) for Cervical and Oropharyngeal Cancer

We have extended our proprietary VST platform to treat other virus-associated cancers. Cervical cancer and oropharyngeal cancer are strongly associated with human papillomavirus (HPV) infection. To increase durability in the tumor microenvironment, HPVSTs are armored with a mutant TGF-β receptor, to counter the suppressive effects of TGF-β, a cytokine commonly secreted in the tumor microenvironment.

HPVSTs are Selected and Expanded From Patient’s Blood

Trial Name:

TT12: CC-OPC HPVST (Phase I)

Indication: Cervical Cancer and Oropharyngeal Cancer

Enrollment Status: Recruiting

Trial Number: NCT02379520

Study evaluating HPV-16/18 E6/E7-Specific T Lymphocytes in patients with Relapsed HPV-Associated Cancers

Learn more at Clinicaltrials.gov

Locations

United States, Texas

Glypican-3 (GPC3) CAR VSTs for Solid Tumors

Tessa has developed a proprietary GPC3-Chimeric Antigen Receptor (CAR) construct which enables the targeting of GPC3-positive tumors.

GPC3-CAR VST Selectively Kills GPC3+ Tumors

GPC3-CAR VSTs travel to the tumor site, where they selectively bind to GPC3 on the surface of the tumor. This binding induces VST signaling leading to the release of cytotoxic granules enabling effective tumor killing.

HER2-CAR VSTs + Oncolytic & Helper Adenovirus for Head & Neck Cancer

Human Epidermal Growth Factor Receptor (HER2) is over expressed in multiple solid tumors, including breast cancer, bladder cancer and head and neck. The overexpression of HER2 is an indicator of poor prognosis, increased recurrence and decreased OS. Our therapy is a two step process, firstly the adenoviruses are infused into the patient followed by HER2-CAR VSTs.

Oncolytic Adenovirus

Selectively replicates and kills tumor cells

Helper-dependent Adenovirus

Expresses the checkpoint inhibitor
PD-L1 and IL-12

HER2-specific CAR VST

Targets and kills HER2 expressing tumor cells